Integrated Clinical Systems, Inc. announces JReview 13.1 – with new AE Incidence Table (nested descending sort AE Table) Report Template, additional Graph Types, and a major new area – Data Quality Analysis for centralized statistical monitoring, and many other features.

Frenchtown, NJ – July 25, 2018

Integrated Clinical Systems, Inc. (ICS) <u>www.i-review.com</u>, developers of Integrated ReviewTM & JReview[®], the world's most comprehensive clinical review and analysis software tool, today announced JReview version 13.1

Here are some of the major highlights of this new JReview version:

<u>Template Reports</u> – major addition to template report area.

Initially introduced in version 13.0 – with the Demographic Summary Table 'template', version 13.1 adds the very commonly used 'AE Incidence Table' to the set. As with the 'demographic summary table' – it's an easy to use drag and drop interface – adding the AE coded term levels to the definition – typically SOC and PT, as well as a 'column' variable – either Study, some other categorical item, etc. and some 'general overview' statistics – to display number of patients with AEs as well as different subsets, for example, number of patients with Serious AEs, etc. The default presentation is in descending order of most frequent SOC reports with PTs nested below, also in descending order of most frequent PT reports. The other very commonly requested feature is to be able to specify a cutoff % - for example – 2, which means that detail levels (PT) entries are only included if at least one of the entries for the PT are at least 2% of the population. And the SOCs are included only if at least one of their PTs meet the cutoff. Interestingly, the cutoff % or cutoff count is also interactive – so users can experiment with different cutoff % - to see the resulting content. If multiple columns, such as treatment group, are included, the user can choose which to use for descending sort, or <total>. Here's a screenshot of the 'preview' display of the Incidence table – showing the cutoff % selection of 2%:

voa 👅					
ype v	**				
Paneis	Items	Designer Output			
Andomization .	Define New Item Define New Pance		Active	Placebo	Totals
Previous Medication	Define New Term Map	Subject Count	97	99	196
Concomitant Medication	Last Change Date	Patients with AEs	28	27	55
Dosage	Pat ID		20	- 27	
)emography	Visit No.		12	<u> </u>	19
final	Visit Date	Skin and subcutaneous tissue disorders	ļ		
.ab Chemistry	Visit Label	Skin burning sensation	9 (9.3%)	9 (9.1%)	18 (9.2%)
ab Hematology	Protocol	Pruritus	2 (2.1%)	0 (0.0%)	2 (1.0%)
.ab Urinalysis	Investigator	Respiratory, thoracic and mediastinal disorders	i		
averse Events	Pat. No.	Upper respiratory tract infection	3 (3 1%)	1(10%)	4/2.0%)
Avcological Results	Treatment	Caush	4 (4 080	2(2.0%)	2(4.6%)
/itals & Physical Exam	NT. Current Rand Date	Cough	1(1.0%)	2(2.0%)	3(1.5%)
OR KA201.AE DATA	NT StudyID	Sinusitis	2 (2.1%)	1 (1.0%)	3 (1.5%)
'0R. Lab Chem (trt days)	NI Studyib	Nervous system disorders			
OR. LabDays		Headache	4 (4.1%)	4 (4.0%)	8 (4.1%)
OR. Lab Vertical (davs)	×	Surgical and medical procedures	İ		
< >		Surgepr	3 (3 1%)	5 (5.1%)	8 (4 1%)
General		Mussuloskeletel and connective tissue disorders	0 (0.110)		• ()
Name V	alue	Rack pain	2 (2 4 %)	4 (1.0%)	2(15%)
Count type Si	biect Count *		2(2.1%)	1(1.0%)	3(1.5%)
Cutoff number 2	v	Gastrointestinal disorders			
Cutoff type Cu	itoff is count 🔹	Tooth disorder	1 (1.0%)	1 (1.0%)	2 (1.0%)
Decimal places (%) 1	*	Renal and urinary disorders			
Descend Sort By <	rotals> -	Urinary tract infection	3 (3.1%)	0 (0.0%)	3 (1.5%)
Group row counts					
Heading In	cidence Report				
Include Subject Count					
Nested item sort					
internet internet in pre-	accinaing *				
Item					
Name V	alue				
Function	coded value				
Group Function no	ne				
Item Tr	eatment				
Panel Ra	andomization				

When the user either saves and executes the saved definition from the Object Explorer, or clicks the 'Create Report' button – a window displaying the results is displayed. Please note that the results are also clickable – just like a crosstab – so if the user clicks on any of the cells in the table – they'll see which patients are contained within the count (highlighting those patients in any reports, graphs, patient profiles displayed).

Incidence Report - All Patients

		Z
--	--	---

😐 🍸 🌬

	Active	Placebo	Totals
Subject Count	97	99	196
Patients with AEs	28	27	55
	12	7	19
Skin and subcutaneous tissue disorders			
Skin burning sensation	9 (9.3%)	9 (9.1%)	18 (9.2%)
Pruritus	2 (2.1%)	0 (0.0%)	2 (1.0%)
Respiratory, thoracic and mediastinal disorders			
Upper respiratory tract infection	3 (3.1%)	1 (1.0%)	4 (2.0%)
Cough	1 (1.0%)	2 (2.0%)	3 (1.5%)
Sinusitis	2 (2.1%)	1 (1.0%)	3 (1.5%)
Nervous system disorders			
Headache	4 (4.1%)	4 (4.0%)	8 (4.1%)
Surgical and medical procedures			
Surgery	3 (3.1%)	5 (5.1%)	8 (4.1%)
Musculoskeletal and connective tissue disorders			
Back pain	2 (2.1%)	1 (1.0%)	3 (1.5%)
Gastrointestinal disorders			
Tooth disorder	1 (1.0%)	1 (1.0%)	2 (1.0%)
Renal and urinary disorders			
Urinary tract infection	3 (3.1%)	0 (0.0%)	3 (1.5%)

Scheduling

The 'print server/scheduling server' has been updated – supporting multiple 'threads' (configurable max number of threads), to multiple jobs at the same time. Scheduling of patient profiles and patient narratives continues to be supported as an optional module.

Graph Browser

More control over graph properties – more colors – including more subdued colors as default, line thickness, symbol size, etc.

Continuing the addition of several graph patterns/types popular in oncology – version 13.1 adds two new graph types - a mean plus/minus standard error line chart and spider plot.

Line Chart - Mean +- SE (Standard Error)

The error bars included in this line chart are Standard Error bars. Previously, only Std Dev was available.

Here's an example screenshot:



The **spider plot** is used to display data over time (calculating days since a reference date on the fly), and by default plotting change from baseline values of the item on the y-axis. Here's the definition window, and a preview.



Here's a generated spider plot, with filter controls, to include/exclude specific groups, sites, etc.



General - HRZ panels throughout

Previously, the HRZ panels (Vertical to Horizontal Panel definitions) were only available in the New UI in Graphs and Reports. Now – HRZ panels appear throughout JReview- including their use in Patient Selection Criteria, Output Filter, and any of the browser definition areas.

AE Risk Assessment

Added ability to export Risk Assessment information at multiple levels. After executing an AE Risk Assessment – the user can select 'File ... Export' – which displays the following dialog – where they can select if they want to export the details of the AE Risk Assessment – with All Levels of MEDDRA terms, or just the top level. Also – another option is to export the presentation (graphics).

Export		\mathbf{X}					
?	• Export to Excel	Levels Ill Levels Top Level Only					
	O Export Presentation						
	OK Ca	ncel					

If the user selects 'Export to Excel ... All Levels' – here's an example screenshot of the display – which includes a column for each of the MEDDRA levels that were included in the AE Risk Assessment – in this case SOC and PT, with the SOC repeated on each row for each PT:

Metric: Relative Risk Ratio (zero events corrected to	0.5)							
Treatment Group: Active								
Reference Group: Placebo								
Patient Subgroup: All Patient Subgroups (N=196)								
MedDRA Level: SOC								
Excluded Range:								
Date: March 15, 2018 12:13:34 PM EDT								
Treatment Groups	Size							
Active	97							
Placebo	99							
SOC	PT	Relative Risk Ratio	Lower CI Limit	Upper CI Limit	Occurrences in Treat	Ratio in Treatment	Occurrences in Refer Ratio	o in Reference
Renal and urinary disorders		7.144	0.371	137.514	3	0.031	0	0.000
Renal and urinary disorders	Urinary tract infection	7.144	0.371	137.514	3	0.031	0	0.000
Blood and lymphatic system disorders		3.062	0.125	74.848	1	0.010	0	0.000
Blood and lymphatic system disorders	Ecchymosis	3.062	0.125	74.848	1	0.010	0	0.000
Immune system disorders		3.062	0.125	74.848	1	0.010	0	0.000
Immune system disorders	Hypersensitivity	3.062	0.125	74.848	1	0.010	0	0.000
Psychiatric disorders		3.062	0.125	74.848	1	0.010	0	0.000
Psychiatric disorders	Somnolence	3.062	0.125	74.848	1	0.010	0	0.000
Reproductive system and breast disorders		3.062	0.125	74.848	1	0.010	0	0.000
Reproductive system and breast disorders	Vaginal infection	3.062	0.125	74.848	1	0.010	0	0.000
Vascular disorders		3.062	0.125	74.848	1	0.010	0	0.000
Vascular disorders	Ecchymosis	3.062	0.125	74.848	1	0.010	0	0.000
Infections and infestations		2.722	0.744	9.957	8	0.082	3	0.030
Infections and infestations	Urinary tract infection	7.144	0.371	137.514	3	0.031	0	0.000
Infections and infestations	Upper respiratory tract infect	3.062	0.324	28.929	3	0.031	1	0.010
Infections and infestations	Vaginal infection	3.062	0.125	74.848	1	0.010	0	0.000
Infections and infestations	Sinusitis	2.041	0.188	22.146	2	0.021	1	0.010
Infections and infestations	Tooth abscess	0.340	0.014	8.317	0	0.000	1	0.010
Musculoskeletal and connective tissue disorders		1.531	0.262	8.963	3	0.031	. 2	0.020
Musculoskeletal and connective tissue disorders	Arthritis	3.062	0.125	74.848	1	0.010	0	0.000
Musculoskeletal and connective tissue disorders	Back pain	2.041	0.188	22.146	2	0.021	1	0.010
Musculoskeletal and connective tissue disorders	Myalgia	0.340	0.014	8.317	0	0.000	1	0.010
Respiratory, thoracic and mediastinal disorders		1.225	0.387	3.881	6	0.062	5	0.051
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract infect	3.062	0.324	28.929	3	0.031	1	0.010
Respiratory, thoracic and mediastinal disorders	Respiratory disorder	3.062	0.125	74.848	1	0.010	0	0.000
Respiratory, thoracic and mediastinal disorders	Sinusitis	2.041	0.188	22.146	2	0.021	1	0.010
Respiratory, thoracic and mediastinal disorders	Cough	0.510	0.047	5.537	1	0.010	2	0.020
Respiratory, thoracic and mediastinal disorders	Pharyngolaryngeal pain	0.340	0.014	8.317	0	0.000	1	0.010
Nervous system disorders		1.099	0.545	2.216	14	0.144	13	0.131
Nervous system disorders	Dizziness	3.062	0.125	74.848	1	0.010	0	0.000
Nervous system disorders	Dysgeusia	3.062	0.125	74.848	1	0.010	0	0.000
Manage system disorders	Sompolonco	3.062	0.125	74 848	1	0.010	0	0.000
Respiratory, thoracic and mediastinal disorders Nervous system disorders	Pharyngolaryngeal pain Dizziness Dysgeusia Somoolooco	0.340 0.340 1.099 3.062 3.062 3.062	0.014 0.545 0.125 0.125 0.125	8.317 2.216 74.848 74.848 74.848	0 14 1 1 1	0.000 0.144 0.010 0.010	1 13 0 0	0.010 0.131 0.000 0.000 0.000

Data Quality Analysis - major new area

A major new capability has been added to JReview version 13.1 – which provides an 'unsupervised' centralized statistical review of data in a trial – on an ongoing basis – directly against the data accessed by JReview. This area runs a battery of tests against the data – including duplicate patient detection, and a wide range of statistical tests, then generates a 'global score' for each geographic area (country, for example), and each site within the region. The data to be included in the evaluation, as well as which tests should be included (default is all the tests that are included), plus weighting factors for generating the global score from the contributing tests – can all be selected/modified by the user setting up the definitions. Here's a walk-through of the results – once an analysis has been conducted, followed by an overview of the definition area.

1. An overview display under the 'Statistical Analysis' tab, and 'Site Score Treemap' – shows the coloration of 'global score' – sites within country (optional level). When click on one of the sites, the darker color, the higher the 'global score' – the table below displays the 'analysis details' behind the global score.



When you click on the 'Site Analysis Table' or 'Geo Location Analysis Table' – (Geo Location in this screenshot) – you see the countries, and their respective 'global score', and the results of each of the specific analyses – a check mark means that country was 'flagged' for that analysis ... and each of the flagged analyses contribute to the 'global score' based on weighting factors that are defined in the definition screen – described below. If one of the analyses is blank (no checkbox) – that means the analysis wasn't run – due to either not enough information, or the user had asked that the analysis not be included. Clicking on any of the country lines – updates the 'Analysis Details' table on the bottom of the window.

te Scores TreeMap Site A	Analysis Ta	able Geo Location	n Analysis Tal	ble											
ocation	Score	Category Check	Correlation	Digit Preference Leading	Digit Preference Trailing	Distribution Check	Dropout Rate	Duplicate Patients	Duplicate Records	Inliers	Integer Check	Missing Category	Missing Continuous	s Outliers	SAE Check
aly	16		V	V									V		7
rance	11												V		
ISA	8		V	V	7	V			V				V		
ngland	4			V									V		(m)
ussia	2												V		
Analysis Detail Taly				n urbe											
Analysis Detail Taly Test		Category		P-Value	Rate										
Analysis Detail taly Test Sorrelation		Category Correlation		P-Value 0.0	Rate										
nalysis Detai taly Test orrelation hi Square bi Square		Category Correlation Digit Preferen	ce Leading	P-Value 0.0. 0.0	Rate 16 225										
inalysis Detai taly Test orrelation hi Square dingongrav.senimov.teet/Dr	listrihution	Category Correlation Digit Preferen Digit Preferen	ce Leading ce Trailing verk	P-Value 0.0 0.0 0.1	Rate 116 25 0										
nalysis Detail taly Test Orrelation hi Square bi Square olmogorov-Smirnov Test(D	Vistribution)	Category Correlation Digit Preferen Digit Preferen Distribution C ²	ce Leading ce Trailing reck	P-Value 0.0 0.1	Rate 016 225 0 0										
nalysis Detai taly Test orrelation hi Square Jimogorov-Smirnov Test(Di synopri Test Of Equality Of round Bate)istribution) of Variance	Category Correlation Digit Preferen Distribution C S Distribution C Coronal Eate	ce Leading ce Trailing neck neck	P-Value 0.0 0.1	Rate 16 26 17 0 0 0 0 0 0 0 0 0 0 0 0 0										
nalysis Detai Test orrelation hi Square olmogoro-Smirnov Test(Di vordean Dretonce	Nistribution of Variance	Category Correlation Digit Preferen Digit Preferen Distribution Ch Distribution Ch Distribution Ch Distribution Ch	ce Leading ce Trailing reck reck	P-Value 0.0 0.1	Rate 115 225 117 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0										
nalysis Detail taly Test orrelation hi Square hi Square omogorov-smirnov Test(Di omogorov-smirnov Test(Di omogori Rate oropout Rate ucidean Distance	Nstribution of Variance	Category Correlation Digit Preferen Distribution Cf Distribution Cf Distributi	ce Leading ce Trailing neck neck	P-Value 0.0 0.0 0.1	Rate 16 225 0 0 0.057 0.043										
nalysis Detail ialy feat orrelation hi Square Jinogorov-Smirnov Test(Di Square Jongout Rate ucidean Distance ahalanobis Distance ahalanobis Distance	Nstribution	Category Correlation Digit Preferen Digit Proferen Distribution Cf Distribution Cf Distributio	ce Leading ce Trailing neck neck	P-Value 0.0 0.1	Rate 16 26 17 0 0 0.057 0.043 0 0 0										
nalysis Detail aly "est is Guare hi Square Square Square Save Smirnov Test(Di Square State	Xistribution of Variance	Category Correlation Digit Preferen Digit Preferen Digit Preferen Digit Preferen Digit Preferen Digit Preferen Digit Preferen Inlers Inlers Inlers Inlers October 2000 Missing Contin	ce Leading ce Trailing neck leeck	P-Value 0.0 0.1	Rate 16 225 17 0 0 0.057 0.043 0 0 0 0 0 0 0 0 0 0 0 0 0										
nalysis Detai taly Test in Square hi Square ownes Test Of Equality Of vones Test Of Equality Of vones Test Of Equality Of vonout Rate uclidean Distance tahalanobis Distance tahalanobis Distance uches Method	istribution f Variance	Category Correlation Digit Preferen Digit Preferen Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Missing Context Outliers	ce Leading ce Trailing reck reck uous	P-Value 0.0 0.0 0.1	Rate 16 25 17 0 0 0.057 0.043 0 0 0.097 0.039										
inalysis Detail taly Test Jarrelation hi Square hi Square Sangorov-Smirnov Test(Di evene's Test Of Equality Of ropout Rate ucidean Distance Issang Continuous ucidean Distance Issang Continuous ucidean Distance Turba Method noro ucidean Distance	Pistribution of Variance	Category Correlation Digit Preferen Digit Preferen Distribution Cf S Distribution Cf S Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Outliers Outliers	ce Leading ce Trailing teck uous	P-Value 0.0 0.1	Rate 16 26 0 0 0.057 0.043 0 0.087 0.039 0.034										
inalysis Detai taly Test Test In Square Dingorov-snirnov Test(Di evene's Test Of Equality Of ropout Rate udiden Distance Iahalanobis Distance Iahalanobis Distance Iahalanobis Distance Iahalanobis Distance Iahalanobis Distance	istribution f Variance	Category Correlation Digit Preferen Digit Preferen Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Distribution Cf Missing Cortuines Outliers Outliers	ce Leading ce Trailing eck eck eck uous	P-Value 0.0. 0.1	Rate 16 256 177 0										
Analysis Detail (taly Test)orelation)hi Square)hi Square)hi Square)hi Square Thi Square Thi Square)hi Square (talogon-Smirnov Test(Di evens' Test Of Equality Of Yooput Rate (dalanobis Distance inzibis Method nerguartile Range (talolarobis Distance inzibis Method Interguartile Range (talolarobis Distance Indicaton Distance	Nistribution of Variance	Category Correlation Digit Preferen Digit Preferen Digit Preferen Distribution Cf Dispositivation Distribution Cf Dispositivation Distribution Contines Outliers Outliers Outliers	ce Leading ce Trailing neck uous	P-Value 0.0 0.1 0.1	Rate 115 225 127 0										

2. Clicking on the 'Data Distribution' tab – displays a list of tables/datasets in the data, and items/columns within each. Clicking on any of the tables -> Items, then displays the details of a variety of statistics for that item – displayed by country, then clicking on '+' opens the country to display the included sites in the country. The Score (global score) column is included for information, but isn't specific to the item selected – the other statistics are ... but the score is present for information, and sorting purposes. Clicking on any of the countries or sites – then updates the other graphics on the page – data distribution for the item, histogram of distribution, etc.



3. Clicking on the 'Last Digit Preference' tab toward the bottom of the window – displays the digit preference for the country or site – compared to all others:



4. Clicking on the Duplicates tab toward the bottom – displays the possible duplicate patients and 'percent duplicates'. This info is driven by information provided during the definition step – described below:



5. Definition step – done prior to scheduling analysis – selects which variables should be included (checked in the 'general' column, which items should be considered for 'duplicate patient' determination – checking items in the 'Patient Info' column. Next area is 'Categories' – those are the types of analyses that will be conducted – all are included by default. The weight column lets the user change the relative importance of each of the analyses. The definition areas to the right – are for options 'GeoLocation' definition (Country – typically), as well as information for Start and Stop dates (used during some of the analyses), location of an Adverse Event variable (with filtering possible), and Patient Completion information. All of these are considered during some of the analyses.

🛎 Define Data Qual	lity Parameter	s				
Retrieved Object Lev	el: Study	 Save D 	ate: Decembe	r 6, 2017 9:48:40 PM EST		
Save at Object Level	: Study	•				
Veriebles					•	-
variables				Paneis	Items	Geographic Unit (optional) Country, Province. State, or City:
Se	elect All	Unselect All]	Adverse Event		country
			,	Dosage		Start Date
Panel Items	General	Patient	Info	Evaluation		Start Date Item: randomdt
invest			 ^	demograp		Select Condition
patho				final		
Ztp 	V			lab chem		
	V			lab hem		A
	V			lab_urin		
bt			E	labs		
bua	V			medhist		
bun	v			Imported SQL		Stop Date
cab	v			mycology		Stop Date Item: finaldate
cho	V			prevmed		Select Condition
db	V			randomiz		Edit
co2	V			vitals		
glu	1					A
qtp			-			
Categories						▼
Category		Included	Weight			Define Adverse Event Variable
Category Check			2 _1	<		Adverse Event Item:
Correlation		V	1	There		sesevere
Digit Preference Lea	ading	1	3	Item		
Digit Preference Tra	ailing	V	2	Name Valu	2	Select Condition
Distribution Check		v	1			= 2 3
Dropout Rate		V	1 🚽			
Duplicate Patients		7	10 🕌			
Duplicate Records		V	1			
Inliers		v	1 🗸			Define Completed Variable
Integer Check		v	5 🚽			Completed Item:
Missing Category		V	3 🗸			complete
Missing Continuous		V	1 +			Select Condition
Outliers		V	0 v			
SAE Check		v	,2 v.			= No
P						al
						Save Reset Delete Retrieved Definition Cancel

About JReview[®]

JReview[®] is the fastest, easiest way to review, graph, report, and analyze your clinical data. It is a webenabled software application written specifically for pharmaceutical, biotech and medical device companies doing clinical research. It provides many vital tools needed to perform clinical data review, ad hoc reporting, data visualization, analysis, and risk assessment of clinical studies data. By interacting with various patient subsets and using any combination of browser modules or dashboards within the product, users can easily review and/or monitor their clinical trials for safety, efficacy, etc.

About Integrated Clinical Systems, Inc.

Integrated Clinical Systems, Inc. (ICS) <u>http://www.i-review.com</u>, headquartered in Frenchtown, NJ, is an industry-leading developer of software applications for pharmaceutical, biotech and medical device companies worldwide. Their original software application, Integrated Review[™], provides ongoing, realtime review of clinical data and an easy-to-use, intuitive means of profiling patients, reporting, graphing, ad-hoc data mining and signal detection for clinical data stored in third-party or in-house data management software systems or data warehouses. This functionality has been ported to a web-enabled software application, JReview[®], and has been expanded even more with new features. These products have been developed by professionals from the pharmaceutical industry, and they continue to be refined and enhanced by customer and FDA feedback. It is this specialization and industry focus that provides their clients with the reporting and analysis capabilities that allow them to bring products to the market safely, efficiently, speedily and cost effectively.

Integrated ReviewTM is trademarked and JReview[®] is a registered trademark of Integrated Clinical Systems, Inc. Copyright © 2018. All rights reserved.

For Further Information

Eric S. Herbel, President Integrated Clinical Systems, Inc. 900 State Hwy 12 Frenchtown, NJ 08825 908-996-3312 <u>eherbel@i-review.com</u>

###